Revefenacin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Uma Maveli[2]

Adult Indications and Dosage

• The agreed dosage is 175 micrograms per day
  • Taken via a standard jet nebulizer (turns liquid medication into mist) connected to an air compressor
  • Makes it easy for patients with pulmonary problems

Contradictions

Hypersensitivity under any ingredient in Revefenacin

Adverse Reactions

Side Effects

• Headache
• Cough
• Problems regarding the upper respiratory system
• Back Pain

Drug Interactions

• Revefenacin and active metabolite (when drug is metabolized by the body into a modified form) are not affected severely smoking status

Use in Specific Populations

• Revefencin is not affected majorly by age, weight, or gender
• Hepatic impariment has not been studied to see if there are necessary precautions to take
• Patients with renal impariment
  • Mesure for antimuscarinic adverse events or the inhibitting of acetocholine, a neurotransmitter in the PNS

IV Compatibility

• Intravenous solution in healthy volunteers
  • Volume of distribution was 218 L
  • Intravenous solution radioactivity:
  • 54% came out as solid waste
  • 27% came out as liquid waste

Pharmacology

See Clinical Studies

Clinical Studies

Trials:

• Revefenacin proved to have long duration of action and low systemic exposure (doesn't affect the whole body) for patients struggling with Chronic Obstructive Pulmonary Disease or COPD
• 88 mcg of this drug can result in constructive bronchodilation (to helps patients breathe better)

Pharmacology trials:

• Evaluted human recombitance mAChRs (muscarinic cholinergic receptor) by testing it on airway tissues from rats, guinea pigs, and humans
  • Revefenacin proved high affinity for the human tissue and competed against those five human recombinant mAChRs
  • This drug attacked "mAChRs mediated contractile responses"
  • This shows that revefenacin produces long-lasting attacking effects on this tissue from rats, guinea pigs, and humans

Conclusion:

• Revefenacin has the potential to be a daily dose broncholdilator for patients struggling from COPD

How is it supplied

• Given to patients via jet nebulizer

Patient Counseling Information

• Currently Running a 52 week phase three trial for patients with severe OCPD

Precautions with Alcohol

There is limited information on Alcohol-Revefencin interactions. Talk to your doctor for further instruction on consuming alcohol with Revefenacin.

Brand Names

• Yupelri